pillbase.ru

Minjuvi

Active substance: tafasitamab

tafasitamab

Centralised EU authorisationActive

Marketing holder: Incyte Biosciences Distribution B.V.

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
RU 1
  • Минджуви®
    лиофилизат для приготовления концентрата для приготовления раствора для инфузий, 200 мг, 200 мг (original in Russian, GRLS)
    ЛП-№(015103)-(РГ-RU)
    Общество с ограниченной ответственностью "Свикс Хэлскеа" (ООО "Свикс Хэлскеа")
US 2
  • MONJUVI
    INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · TAFASITAMAB 200 mg/5mL
    50881-013
    Incyte Corporation
  • MONJUVI
    INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · TAFASITAMAB 200 mg/5mL
    73535-208
    Incyte Corporation
Import and control

Control by country

  • Russiaprescription only

    Source: GRLS (Russian state register) · record 01a120c3-e9e5-7c77-9c17-c82d27f8e1c3;count=1 · valid from 2026-10-09 · verified 2026-10-09

  • United Statesprescription only

    Source: openFDA NDC · record 01a12098-be81-7a3f-a89d-c200e8189972,01a1209c-1ef6-7291-be2f-aad2d96bae9b;count=2 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/005436
Registration status
Active
ATC code
L01FX12
Sources
  • product · EMA · EMEA/H/C/005436 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/005436 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/005436 · Verified 2026-10-09